3774 results about "Coronavirus" patented technology

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

The invention discloses an anti-SARS-CoV-2 fully-humanized monoclonal antibody against SARS-CoV-2. The antibody is obtained by screening through a flow sorting-single cell PCR technology, and has a unique CDR partition. The invention further discloses an application of the antibody in preparation of medicines for treating the 2019-coronavirus disease. The monoclonal antibody disclosed by the invention has efficient and specific anti-SARS-COV-2 activity, also has the characteristics of high expression, complete humanization and good stability, and is suitable for industrial production.

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

The invention relates to a preparation method for a vaccine capable of treating and / or preventing SARS-CoV-2 infection or COVID-19 diseases. The core antigen of the vaccine comprises the RBD (receptor binding zone) fusion protein of the SARS-CoV-2, and a vaccine form comprises an RBD fusion protein subunit vaccine, an RBD fusion protein mRNA vaccine or an RBD fusion protein adenovirus vector vaccine. The above vaccine immunizes an organism, and immune reaction for treating and / or preventing the SARS-CoV-2 infection can be generated so as to be used for treating and / or preventing COVID-19. The invention also relates to an RBD fusion gene, the RBD fusion protein, a carrier, a cell, a preparation method, a treatment method or a pharmacy purpose of the SARS-CoV-2.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. Specifically, the present inventionrelates to an anti-novel coronavirus monoclonal antibody, and a composition (e.g., a diagnostic agent and a therapeutic agent) comprising the antibody. Furthermore, the invention also relates to an application of the antibody. The antibody provided by the invention can be applied to diagnosis, prevention and / or treatment of infection of the novel coronavirus and / or diseases (e.g., novel coronavirus pneumonia) caused by the infection.

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picomoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 1240 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus.

Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and / or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and / or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and / or alternation with one or more other anti-viral agents.

The invention relates to a neutralizing antibody for resisting a novel coronavirus SARS-Cov-2 and an application of the neutralizing antibody. The antibody at least comprises one of a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3. The antibody can be used for preparing a diagnostic reagent or a diagnostic kit, a drug or a pharmaceutical composition for detecting, preventing and treating a COVID-19. According to the neutralizing antibody, differential antibody screening is carried out through a phage display technology ina manner of targeting SARS-Cov-2-RBD and SARS-Cov-1-RBD; the neutralizing antibody for resisting the novel coronavirus SARS-Cov-2 is obtained; binding of the SARS-Cov-2-RBD and ACE2 positive cells can be blocked; and the neutralizing antibody has a remarkable virus neutralizing effect on an SARS-Cov-2 pseudo virus and provides an effective alternative antibody drug for prevention and treatment ofthe COVID-19.

The invention provides a detection kit of IgM / IgG antibodies of novel coronavirus (SARS-CoV-2), and relates to the technical field of biology. According to the detection kit of IgM / IgG antibodies of novel coronavirus (SARS-CoV-2), the IgM / IgG antibodies of novel coronavirus (SARS-CoV-2) are detected through adoption of a colloidal gold capture method, a colloidal gold indirect method and a colloidal gold double antigen sandwich method, wherein adopted antigens are highly active recombinant antigens which are obtained through fusion expression of N protein fragments and S protein dominant epitope fragments, and colloidal gold is labeled indirectly, so that steric hindrance is reduced, and the activity, reaction consistency and accuracy of the antigens are increased. Since a sample pad is pretreated, the interference of complex components in a blood sample to a reaction can be reduced greatly, the detection kit has no requirements for instruments during detection, simple and flexible operation, direct and manual interpretation of results and a short test time, the results can be interpreted in only 15 minutes, and the test results are accurate.

The invention discloses a colloidal gold kit for jointly detecting coronavirus IgM / IgG antibody, and a preparation method thereof, and relates to the field of biological medicine. Whether anti-novel coronavirus nucleocapsid protein IgM antibody and / or anti-novel coronavirus nucleocapsid protein IgG antibody exists in human serum or plasma or not by adopting an antigen-antibody sandwich method anda colloidal gold immunochromatography method principle, the novel coronavirus nucleocapsid protein containing 6xHis mark is marked by applying colloidal gold, thereby forming gold-marked N protein tobe adsorbed on a gold-marked pad, the novel coronavirus nucleocapsid protein containing 6xHis mark is used as an indication marker, the mouse-anti-human u chain monoclonal antibody is coated on the IgM detection line of a NC membrane, the mouse-anti-human IgG monoclonal antibody is coated on the IgG detection line and the mouse-anti 6xHis monoclonal antibody is coated on a quality control line ofthe NC membrane, the qualitative detection of the anti-novel coronavirus nucleocapsid protein IgG antibody is realized, and the colloidal gold kit disclosed by the invention has the advantages of being convenient to use, high in sensitivity and short in detection time.

The invention relates to an SARS-CoV-2 (severe acute respiratory syndrome-corona virus disease-2) inhibitor and application thereof and in particularly relates to a neutralizing antibody for SARS-CoV-2 and application of the neutralizing antibody. According to the antibody, a phage display technology is adopted to construct a high-capacity human immunity phage antibody library, and an SARS-CoV-2 protein is adopted a target, human antibody single-chain antibody fragments are screened, and an antibody with a good neutralizing function on SARS-CoV-2 viruses is obtained. The antibody provided by the invention can be used for treating diseases caused by infection of novel corona viruses, and has significant clinical application value.

The invention discloses a novel coronavirus pneumonia (COVID-19) serological diagnosis kit. The kit comprises an S-IgM / IgG test strip and an N-IgM / IgG test strip, the double-antigen quadruple detection kit can be used for simultaneously detecting four indexes of an IgM / IgG antibody for resisting novel coronavirus spinous process protein S and an IgM / IgG antibody for resisting novel coronavirus nucleocapsid protein N in serum of a patient suffering from novel coronavirus pneumonia COVID-19. According to the kit, the detection sensitivity is improved through quantum dot fluorescence labeling andmultistage coupling amplification signals, the detection accuracy is improved through double-antigen quadruple detection, and the biological safety in the detection process is guaranteed by establishing a virus inactivation system. The kit is suitable for whole blood, plasma and serum detection, and can be applied to novel COVID-19 serological diagnosis.

The invention belongs to the technical fields of biochips and diagnostic reagents, and discloses a method for detecting various respiratory viruses, and primers and probes thereof. In the invention, nucleotide sequences of 14 respiratory viruses, namely adenovirus, human metapneumovirus, influenza virus A, influenza virus B, respiratory syncytial virus, bocavirus, rhinovirus, coronavirus (HKU1, NL63 and SARS), and parainfluenza virus (type I, type II, type III and type IV) are analyzed, and corresponding reverse transcription primers, PCR primers and specific probes are designed. Specific gene segments are amplified by reverse transcription and multiple asymmetric PCR methods; a fluorescence-coded microsphere group coupled with the virus specific probes and the PCR amplification product are incubated and hybridized by liquid phase chip technology; and finally the Bio-PlexTM200 is used for detection. The detection method has the advantages of high flux, high specificity and sensitivity, stable results and good repeatability, the detection method is easy to operate, and the detection speed is high.

The invention relates to an SARS-CoV-2 neutralizing antibody detection kit. The SARS-CoV-2 neutralizing antibody detection kit comprises a solid phase carrier, an S protein antigen of SARS-CoV-2 and acompetitive substance. The competitive substance is marked with a signal substance and can be specifically combined with the new coronavirus S protein antigen. Whether a tested person is infected bythe new coronavirus or not and whether infection risks exist or not are judged by detecting a neutralizing antibody through an immunodiagnosis technology, and the method is reliable in theory, practical and feasible and can be completed only in a secondary biosafety laboratory.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain. Further, products incorporating the antimicrobial compositions of the present invention and methods of using the antimicrobial compositions and products are disclosed herein.

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

The invention relates to traditional Chinese medicine compositions, and specifically discloses a prescription capable of treating pneumonia caused by 2019-nCoV (a novel coronavirus) infection as wellas application thereof. The prescription capable of treating the pneumonia caused by the 2019-nCoV infection comprises the following traditional Chinese medicine materials as raw materials in parts byweight: 9 parts of ephedra, 6 parts of roasted liquorice roots, 9 parts of apricot kernels, 15-30 parts of raw gypsum, 9 parts of cassia twigs, 9 parts of oriental waterplantain rhizome, 9 parts of zhuling, 9 parts of white atractylodes rhizomes, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of baical skullcap roots, 9 parts of ginger processed pinellia tubers, 9 parts of fresh ginger, 9 parts of aster, 9 parts of common coltsfoot flowers, 9 parts of blackberry lily rhizome, 6 parts of manchurian wildginger, 12 parts of Chinese yams, 6 parts of immature orange fruits, 6 parts of dried orange peel, and 9 parts of wrinkled gianthyssop herb. In combination with symptom manifestation of the pneumonia caused by the 2019-nCoV infection, the invention adopts an optimized and integrated traditional Chinese medicine prescription, thereby achieving synergistic treatment effects. According to current treatment results of diagnosed patients of different ages in many provinces and regions, the prescription capable of treating the pneumonia caused by the 2019-nCoV infection has true curative effects that the response rate is up to 95.12%.

The invention relates to the technical field of biology, and specifically provides a detection kit for a detection kit for antigens of a novel coronavirus (SARS-CoV-2). According to the detection kitprovided by the invention, the antigens of the SARS-CoV-2 are detected by virtue of a colloidal gold double antibody sandwich method, and two monoclonal antibodies and colloidal gold are mixed for labeling, so that a detection result of the antigens of the SARS-CoV-2 is accurate and high in sensitivity, and meanwhile, the detection rate can be remarkably increased. According to the detection kit,a blank in immunological detection of the SARS-CoV-2 is filled up, and field detection can be realized without a detection instrument, so that the time and the labor are saved, and operation is flexible.

Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respitory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.

The invention provides a novel coronavirus ORF1ab gene nucleic acid detection kit, and particularly discloses a kit for detecting the ORF1ab gene of the novel coronavirus and a method thereof, which have extremely high sensitivity and specificity.

The invention relates to the technical field of medical biology, and specifically discloses a novel coronavirus (SARS-COV-2) spike protein binding molecule and applications thereof. The binding molecule can specifically bind the spike protein of SARS-COV-2 and includes at least one immunoglobulin single variable structural domain. The provided binding molecule can specifically bind the SARS-COV-2-Spike protein and effectively block the binding of the SARS-COV-2-Spike protein and human cell ACE2 receptors, so that the infection process of the SARS-COV-2 on cells can be further blocked, and theinfection and amplification of the SARS-COV-2 can be inhibited.

The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.

The present invention belongs to the field of biomedicine, and relates to polypeptides capable of inhibiting human coronavirus infections, particularly to polypeptides capable of inhibiting human coronavirus infections in a broad spectrum manner, and applications thereof. According to the present invention, the polypeptides capable of providing broad spectrum inhibition effects for infections caused by more than 2 human coronaviruses are provided based on the conservation property of the S2 region of a coronavirus S protein and the similar fusion mechanism; the test results show that the polypeptides can achieve the commonality of the human coronavirus, ie., the similar HR region and the same fusion mechanism mediated by the coronavirus S protein so as to provide a series of HCoV-EK polypeptides, wherein the polypeptides provide good inhibition effects for currently popular human coronaviruses, and further provide good inhibition activity for SARS virus (RsSHC014-CoV or RsW1V1-CoV) possibly infecting human; and the polypeptides of the present invention can provide the prevention and treatment candidate drug for the currently popular human coronaviruses and the novel human coronavirus possibly emerging in the future.

Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.

The invention discloses a fluorescence immunochromatography device for detecting a novel coronavirus COVID-19 and a using method of the fluorescence immunochromatography device. The fluorescence immunochromatography device disclosed by the invention is high in sensitivity and strong in specificity, the accuracy is high, the detection sensitivity can reach 10pg / ml, the detection speed is high, theoperation is simple, the device is portable, the requirement for personnel is low, the operation of professionals is not needed, the detection cost is low, the device can be applied to preliminary screening of various places such as hospitals, airports, customs and disease control centers, the detection time (10-15 min) is short, a simpler, more convenient and faster field detection means is provided for suspected patient investigation and asymptomatic infected person screening, and therefore epidemic spreading is prevented as soon as possible.

The invention discloses a nucleic acid composition, a kit and a method for detecting 2019 novel coronaviruses, belonging to the technical field of biology. The nucleic acid composition disclosed by the invention comprises at least one selected from the group consisting of a first nucleic acid combination and a second nucleic acid combination, wherein the first nucleic acid combination comprises nucleic acids as shown in SEQ ID NO.4-6, and the second nucleic acid combination comprises nucleic acids as shown in SEQ ID NO.7-9. When the nucleic acid composition, the kit or the method provided by the invention is used for detecting the 2019 novel coronaviruses, higher sensitivity and higher specificity are achieved.

The invention discloses a novel coronavirus S protein double-region subunit nano vaccine based on pyrococcus furiosus ferritin. The virus receptor binding domain (RBD) and fusion peptide (FP) are usedtogether as a double antigen, and are connected with pyrococcus furiosus ferritin (PF_Ferritin) to from a fusion protein RBD-FP-PF_Ferritin to realize antigen multimerization; and then an eukaryoticcell expression system is used for expressing, and a 24-mer nano antigen can be formed through self-assembly of PF_Ferritin. The scheme can overcome the shortcoming of insufficient immunogenicity of RBD monomers, the obtained vaccine can significantly increase the level of a neutralizing antibody against the virus of a host, and the produced antibody has the ability to strongly block the virus from invading target cells. In addition, the vaccine of the invention is simple in preparation method, is easy to purify, and is high in safety, and the vaccine can be relatively quickly applied to clinical trials.